PT2668959E - Compostos imunogénicos compreendendo o péptido gp41 do vih acoplado à proteína transportadora crm197 - Google Patents

Compostos imunogénicos compreendendo o péptido gp41 do vih acoplado à proteína transportadora crm197 Download PDF

Info

Publication number
PT2668959E
PT2668959E PT123056020T PT12305602T PT2668959E PT 2668959 E PT2668959 E PT 2668959E PT 123056020 T PT123056020 T PT 123056020T PT 12305602 T PT12305602 T PT 12305602T PT 2668959 E PT2668959 E PT 2668959E
Authority
PT
Portugal
Prior art keywords
understanding
peptide coupled
immunogenic compounds
transporting protein
protein crm197
Prior art date
Application number
PT123056020T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Innavirvax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innavirvax filed Critical Innavirvax
Publication of PT2668959E publication Critical patent/PT2668959E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K16/1145
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PT123056020T 2012-05-31 2012-05-31 Compostos imunogénicos compreendendo o péptido gp41 do vih acoplado à proteína transportadora crm197 PT2668959E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305602.0A EP2668959B1 (en) 2012-05-31 2012-05-31 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein

Publications (1)

Publication Number Publication Date
PT2668959E true PT2668959E (pt) 2015-02-05

Family

ID=48793339

Family Applications (1)

Application Number Title Priority Date Filing Date
PT123056020T PT2668959E (pt) 2012-05-31 2012-05-31 Compostos imunogénicos compreendendo o péptido gp41 do vih acoplado à proteína transportadora crm197

Country Status (21)

Country Link
US (1) US9511136B2 (cg-RX-API-DMAC7.html)
EP (2) EP2668959B1 (cg-RX-API-DMAC7.html)
JP (1) JP6352251B2 (cg-RX-API-DMAC7.html)
KR (1) KR102077876B1 (cg-RX-API-DMAC7.html)
CN (1) CN104507496B (cg-RX-API-DMAC7.html)
AU (1) AU2013269120B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014029861B1 (cg-RX-API-DMAC7.html)
CA (1) CA2875162C (cg-RX-API-DMAC7.html)
DK (1) DK2668959T3 (cg-RX-API-DMAC7.html)
EA (1) EA027803B1 (cg-RX-API-DMAC7.html)
ES (2) ES2528109T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150058T1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN10128A (cg-RX-API-DMAC7.html)
MX (1) MX360206B (cg-RX-API-DMAC7.html)
PL (1) PL2668959T3 (cg-RX-API-DMAC7.html)
PT (1) PT2668959E (cg-RX-API-DMAC7.html)
RS (1) RS53769B1 (cg-RX-API-DMAC7.html)
SI (1) SI2668959T1 (cg-RX-API-DMAC7.html)
UA (1) UA118542C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013179262A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201409023B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335119A1 (en) * 2004-02-06 2014-11-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
TWI740823B (zh) * 2015-04-17 2021-10-01 澳大利亞商保健樂科技昆士蘭有限公司 疫苗組成物及其用途
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184973A1 (en) * 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
TWI379839B (en) * 2003-12-17 2012-12-21 Wyeth Llc Aβ immunogenic peptide carrier conjugates and methods of producing same
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine
US7965010B2 (en) * 2008-09-03 2011-06-21 Bose Corporation Linear motor with patterned magnet arrays
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method

Also Published As

Publication number Publication date
KR20150032266A (ko) 2015-03-25
US9511136B2 (en) 2016-12-06
MX360206B (es) 2018-10-24
PL2668959T3 (pl) 2015-04-30
CN104507496A (zh) 2015-04-08
EP2854846A1 (en) 2015-04-08
AU2013269120B2 (en) 2017-04-20
WO2013179262A1 (en) 2013-12-05
AU2013269120A1 (en) 2014-12-18
CA2875162C (en) 2021-09-14
ES2528109T3 (es) 2015-02-04
BR112014029861A2 (pt) 2017-07-25
IN2014DN10128A (cg-RX-API-DMAC7.html) 2015-08-21
UA118542C2 (uk) 2019-02-11
KR102077876B1 (ko) 2020-02-14
EP2668959A1 (en) 2013-12-04
US20150147348A1 (en) 2015-05-28
EA201491969A1 (ru) 2015-04-30
RS53769B1 (sr) 2015-06-30
CN104507496B (zh) 2018-08-03
EA027803B1 (ru) 2017-09-29
JP6352251B2 (ja) 2018-07-04
HRP20150058T1 (hr) 2015-04-10
ZA201409023B (en) 2016-08-31
ES2701084T3 (es) 2019-02-20
MX2014014526A (es) 2015-06-02
EP2854846B1 (en) 2018-09-12
CA2875162A1 (en) 2013-12-05
SI2668959T1 (sl) 2015-03-31
DK2668959T3 (en) 2015-01-26
JP2015519359A (ja) 2015-07-09
BR112014029861B1 (pt) 2022-05-24
EP2668959B1 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
FR24C1019I2 (fr) Anticorps anti-fcrn
DK3054991T3 (da) Protein-polymer-lægemiddelkonjugater
EP2753345A4 (en) POLYPEPTIDIMPFSTOFF
DK3054992T3 (da) Protein-polymer-lægemiddelkonjugater
IL230838A0 (en) Pharmaceutical compositions
DK3117837T3 (da) Antistofformuleringer
HUE056014T2 (hu) Lipidek gyógyszerszállító készítményekhez
HRP20181447T1 (hr) Pripravci glp-1 peptida i njihova priprava
IL226307A0 (en) Compounds and methods for treating pain
DK2858676T3 (da) Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater
EP3427721C0 (en) HIGH CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS
DK3444281T3 (da) Forbedrede peptidlægemidler
EP2930240A4 (en) ANTI-FOLR1 ANTIBODY
DK2844286T3 (da) Lyofiliserede og vandige anti-CD40-antistofformuleringer
EP2928463A4 (en) LYOPHILIZED PREPARATIONS OF MELPHALAN FLUFENAMIDE
EP2837685A4 (en) ANTI-FGFR2 ANTIBODY
EP2739300A4 (en) N-TERMINATED REMOTE GP120 IMMUNOGENESE
KR102355959B9 (ko) 158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트
EP2876161A4 (en) VACCINE
HUE045668T2 (hu) Oldat készítmények módosított anti-IL-23p19 antitestekbõl
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
BR112014005756A2 (pt) vacina
DK2917244T3 (da) Aprotinin-afledte polypeptid-antistofkonjugater
PT2668959E (pt) Compostos imunogénicos compreendendo o péptido gp41 do vih acoplado à proteína transportadora crm197
CL2014002180A1 (es) Peptidos antomicrobianos